Molecular and Cellular Pharmacology, Vol 9, No 3 (2017)

Font Size:  Small  Medium  Large

FDA Approves First Once-Monthly Buprenorphine Injection, a Medication-assisted Treatment Option for Opioid Use Disorder

FDA News Release


The U.S. Food and Drug Administration today approved Sublocade, the first once-monthly injectable buprenorphine product for the treatment of moderate-to-severe opioid use disorder (OUD) in adult patients who have initiated treatment with a transmucosal (absorbed through mucus membrane) buprenorphine-containing product. It is indicated for patients that have been on a stable dose of buprenorphine treatment for a minimum of seven...

Full Text: PDF

LumiText Publishing, P.O. Box 774, Ellicott City, MD 21041 

Copyright © 2008 LumiText Publishing. All rights reserved.